On August 20, 2026, Personalis, Inc. announced receipt of a new task order under its contract with the U.S. Department of Veterans Affairs for the Million Veteran Program (VA MVP). The order is effective September 30, 2026 and has a value of up to $18.3 million, contingent on sample receipt and service performance. This award increases the cumulative value of task orders received under VA MVP contracts to approximately $243.3 million. Personalis operates in the biotechnology industry, providing genomic data analysis services for large-scale research programs.

Personalis, Inc. reported financial results for the quarter ended June 30, 2026, announcing total revenue of $22.4 million, a 30% increase from $17.2 million in the prior year period. Clinical test volume surged 199% year-over-year to 10,384 tests, driving clinical revenue growth of 442% to $2.6 million. The company secured Medicare coverage approvals for NeXT Personal for immunotherapy monitoring and neoadjuvant breast cancer monitoring. Core pharma testing services revenue rose 51% to $16.8 million, while population sequencing revenue declined 9% to $3.0 million. Personalis ended the quarter with approximately $212.7 million in cash, cash equivalents, and short-term investments. The company will no longer provide financial guidance following its merger agreement with Tempus AI announced on July 20, 2026. Personalis operates in the precision oncology industry, providing advanced genomic testing for cancer detection and monitoring.

Personalis, Inc. entered into a merger agreement with Tempus AI, Inc. to be acquired in a transaction that will result in the company's survival as a wholly-owned subsidiary of Tempus. The consideration for stockholders will consist of a combination of stock and cash, with a potential cash election by Tempus for up to 50% of the outstanding shares at $16.25 per share. Personalis, Inc. operates in the healthcare and genomics industry, providing personalized medicine solutions.

Personalis, Inc. entered into a definitive agreement to be acquired by Tempus AI, Inc. for a total enterprise value of $1.5 billion, net of Tempus's existing ownership interest. Shareholders will receive $16.25 per share in a transaction structured as 100% stock, with Tempus having the option to elect payment in cash for up to 50% of the consideration. Personalis reported preliminary Q2 2026 revenue of $22.4 million. Personalis, Inc. is a genomics company specializing in precision oncology and minimal residual disease monitoring.